Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III radiotherapy plus OSAG 101 (Theraloc) plus temozolomide vs radiotherapy plus temozolomide in newly diagnosed glioblastoma
2005-003101-85Phase 3Completed
- Sponsor
- Oncoscience AG
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nimotuzumab in glioblastoma (GBM) (2 arms), sponsored by Oncoscience AG. Primary endpoint: Progression-free survival. Started Feb 2007; status: completed.
02
Drugs
nimotuzumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2005-003101-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003101-85.